Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain
· Delayed Price · Currency is EUR 80.70
-0.55 (-0.68%)
At close: Mar 5, 2026
BME:ROVI Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 743.48 | 763.75 | 829.51 | 817.7 | 648.68 | Upgrade
|
| Revenue Growth (YoY) | -2.65% | -7.93% | 1.44% | 26.06% | 54.46% | Upgrade
|
| Cost of Revenue | 271.9 | 296.04 | 346.17 | 305.27 | 268.84 | Upgrade
|
| Gross Profit | 471.59 | 467.71 | 483.34 | 512.43 | 379.84 | Upgrade
|
| Selling, General & Admin | 160.47 | 158.26 | 147.02 | 129.99 | 103.36 | Upgrade
|
| Other Operating Expenses | 107.6 | 102.73 | 92.52 | 105.84 | 74.96 | Upgrade
|
| Operating Expenses | 298.45 | 289.01 | 263.87 | 258.69 | 199.68 | Upgrade
|
| Operating Income | 173.14 | 178.71 | 219.47 | 253.74 | 180.15 | Upgrade
|
| Interest Expense | -2.56 | -1.99 | -0.95 | -0.85 | -0.91 | Upgrade
|
| Interest & Investment Income | 0.51 | 0.03 | 0.01 | 0.01 | 0.07 | Upgrade
|
| Earnings From Equity Investments | 0.06 | -0.14 | -0.13 | 0.2 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.21 | 0.3 | -0.09 | -0.82 | -0.18 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.33 | 0.79 | 2.09 | 3.93 | 3.4 | Upgrade
|
| EBT Excluding Unusual Items | 183.26 | 177.69 | 220.41 | 256.21 | 182.72 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 1.76 | - | Upgrade
|
| Asset Writedown | - | - | - | -0 | -0.1 | Upgrade
|
| Pretax Income | 183.26 | 177.69 | 220.41 | 257.97 | 182.63 | Upgrade
|
| Income Tax Expense | 42.9 | 40.81 | 50.11 | 58.3 | 29.55 | Upgrade
|
| Earnings From Continuing Operations | 140.36 | 136.88 | 170.3 | 199.67 | 153.08 | Upgrade
|
| Minority Interest in Earnings | 0.08 | 0.01 | 0.04 | 0 | - | Upgrade
|
| Net Income | 140.44 | 136.88 | 170.34 | 199.67 | 153.08 | Upgrade
|
| Net Income to Common | 140.44 | 136.88 | 170.34 | 199.67 | 153.08 | Upgrade
|
| Net Income Growth | 2.60% | -19.64% | -14.69% | 30.44% | 150.71% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 53 | 53 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 53 | 53 | 55 | Upgrade
|
| Shares Change (YoY) | -0.13% | -3.73% | -0.51% | -3.50% | 0.03% | Upgrade
|
| EPS (Basic) | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 | Upgrade
|
| EPS (Diluted) | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 | Upgrade
|
| EPS Growth | 2.73% | -16.53% | -14.25% | 35.31% | 150.36% | Upgrade
|
| Free Cash Flow | 121.87 | 79.16 | 59.45 | 186.88 | 109.22 | Upgrade
|
| Free Cash Flow Per Share | 2.38 | 1.55 | 1.12 | 3.50 | 1.97 | Upgrade
|
| Dividend Per Share | - | 0.935 | 1.104 | 1.294 | 0.956 | Upgrade
|
| Dividend Growth | - | -15.28% | -14.69% | 35.39% | 150.68% | Upgrade
|
| Gross Margin | 63.43% | 61.24% | 58.27% | 62.67% | 58.55% | Upgrade
|
| Operating Margin | 23.29% | 23.40% | 26.46% | 31.03% | 27.77% | Upgrade
|
| Profit Margin | 18.89% | 17.92% | 20.53% | 24.42% | 23.60% | Upgrade
|
| Free Cash Flow Margin | 16.39% | 10.37% | 7.17% | 22.86% | 16.84% | Upgrade
|
| EBITDA | 195.54 | 199.62 | 238.02 | 271.33 | 196.56 | Upgrade
|
| EBITDA Margin | 26.30% | 26.14% | 28.69% | 33.18% | 30.30% | Upgrade
|
| D&A For EBITDA | 22.39 | 20.91 | 18.54 | 17.59 | 16.41 | Upgrade
|
| EBIT | 173.14 | 178.71 | 219.47 | 253.74 | 180.15 | Upgrade
|
| EBIT Margin | 23.29% | 23.40% | 26.46% | 31.03% | 27.77% | Upgrade
|
| Effective Tax Rate | 23.41% | 22.97% | 22.73% | 22.60% | 16.18% | Upgrade
|
| Advertising Expenses | 18 | 21.74 | 21.75 | 19.99 | 12.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.